{
  "guideline": {
    "id": "PA166328700",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Nateglinide - CYP2C9",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328700",
    "relatedChemicals": [
      {
        "id": "PA450600",
        "name": "nateglinide",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166315222",
      "name": "Recommendation Annotation PA166315222",
      "population": "Affected subgroups: CYP2C9 poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450600",
          "name": "nateglinide",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245922,
        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315221",
      "name": "Recommendation Annotation PA166315221",
      "population": "Affected subgroup: CYP2C9 poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450600",
          "name": "nateglinide",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245921,
        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}